No.
Aysha cannot be declared cancer-free for another 5 years. He had no detectable cancer since his surgery in the UK.
the treatment they wanted was being denigrated by UK doctors
Not true. The NHS was/is spending millions buying Proton Beam equipment.
The debate was regarding adjunctive treatment post-surgery. This is to try to kill any cancer cells that cannot be detected and reduce the risk of recurrence. The doctor's position was that Proton Beam was good for pre-surgical treatment to target the tumour accurately with minimum damage to surrounding tissue, but not for adjunctive therapy where you are delivering radiation to the area around where the tumour was.
Their advice was that even if they had a machine in the next room it was not the tool they would choose.
Aysha has still not received post-op chemo. Stats show that this has reduced his chance of staying free of cancer from 70% to around 50%
The documentary in the UK that presented the case from the perspective of the NHS showed a very different side to the issue. Aysha's parents refused to engage in conversations with the consultants regarding treatment and then twist that into a story about arrogant doctors.
Aysha is alive because of the extreme skill and dedication of NHS surgeons, oncologists and radiotherapists.
Source...
In the treatment of Ashya’s cancer, called medulloblastoma, radiotherapy should take place between four and six weeks after surgery – but Ashya’s did not start until more than seven weeks had passed. More importantly, the doctors say, Ashya’s chances of survival could be affected because he has not had the full treatment package. His parents have refused chemotherapy for him.
While he was based at the Motol hospital in Prague, travelling daily to the private proton therapy clinic, the Kings signed waivers to exempt their son from the drug infusions that doctors had prescribed and the British court had ordered. Brett King, Ashya’s father, said in a TV interview that he did not believe his son needed chemotherapy.
Roger Taylor, professor of clinical oncology at the College of Medicine, Swansea University, said good outcomes for children with Ashya’s condition were achieved only through the full combination of surgery, radiotherapy and chemotherapy.
“It’s only with that package of treatment that you achieve that 70-80% survival,” he said. “We do know from past experience the approximate outcomes without chemotherapy. In North America, there was a trial of two different doses of radiotherapy without chemotherapy. Survival was in the range of 50-55%.”
